Parent Management Training to Treat Irritability
Launched by UNIVERSITY OF COLORADO, DENVER · Aug 25, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a type of therapy called Parent Management Training (PMT) to help children who struggle with irritability, like having frequent temper tantrums or anger outbursts. The study aims to include 18 children aged 3 to 12 years who show significant irritability, and it will involve their parents or guardians in the treatment process. Researchers want to see if PMT can effectively reduce irritability and will measure the children's physiological responses during a task designed to frustrate them, both before and after the training sessions.
To be eligible for the study, children must have noticeable irritability and their parent or guardian must be willing to participate in the treatment. However, children with severe psychiatric issues, such as being a danger to themselves or others, or those currently experiencing serious trauma, are not eligible. Participants can expect to take part in a structured training program alongside their parents, which will help manage their irritability. This trial is currently recruiting, and it aims to gather important information that could shape future treatments for children with similar challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • clinically significant irritability (Clinician Affective Reactivity Index 30 or greater)
- • parent or guardian willing to participate in treatment with the child
- Exclusion Criteria:
- • psychiatric instability (danger to self/others, risky substance abuse)
- • current active Post-Traumatic Stress Disorder (PTSD) or a severe active stressor (e.g. child abuse)
- • history of severe psychopathology with an established alternate treatment (e.g. autism spectrum disorder, bipolar disorder, schizophrenia, intellectual disability)
- • general medical condition that may be driving irritability or prevent generalizable physiologic measures.
- • screen positive for an intellectual disability via Wechsler Abbreviated Scale of Intelligence Second Edition (WASI II) estimated Intelligence Quotient (IQ)\<70.
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Patients applied
Trial Officials
Joel Stoddard, MD
Principal Investigator
University of Colorado Denver, Anschutz Medical Campus
Joel Stoddard, MD
Principal Investigator
University of Colorado Denver Anschutz
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported